INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Teleflex Incorporated and its executives following significant corporate announcements and a sharp decline in stock price [1][2][3]. Group 1: Corporate Announcements - On February 27, 2025, Teleflex announced plans to create a new publicly traded company focused on its Urology, Acute Care, and OEM businesses [2]. - The company entered into a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG for an estimated cash payment of approximately €760 million [2]. - The resignation of Teleflex's Chief Financial Officer was also announced on the same day [2]. Group 2: Stock Price Reaction - Following the announcements on February 27, 2025, Teleflex's stock price fell by $38.52 per share, representing a decline of 21.69%, closing at $139.11 per share [3]. Group 3: Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Teleflex regarding possible securities fraud or other unlawful business practices [1].